The high flow nasal cannula is tested at VMED Group’s laboratory. Petrosetco has sponsored VND1.5 billion for HFNC production to fight Covid-19 - PHOTO: PETROSETCO

HCMC - The Hanoi University of Science and Technology (HUST) has cooperated with the VMED Group to produce high flow nasal cannulas for Covid-19 patients, with the first 30 units in the first phase financed by PetroVietnam General Services Corp. (Petrosetco) at VND1.5 billion.

The BKVM-HF1 high flow nasal cannula made its debut in Hanoi City on July 2.

The high flow nasal cannulas are expected to meet the Covid-19 treatment needs at hospitals and healthcare centers nationwide.

The cannulas can supply continuous high-flow breathing air, with adjustable oxygen concentration. The machine, stable at 37 degrees Celsius and moisture saturation through the frame on the nose, is used to treat patients with respiratory failure.

The machine was measured and tested at the VMED Group lab, tested at the A9 Emergency Center at Bach Mai Hospital and licensed by the Ministry of Health for the treatment of Covid-19 patients.

Associate Professor Dr. Nguyen Van Chi from the A9 Emergency Center at Bach Mai Hospital said the HFNC plays an important role in the Covid-19 fight, especially in treating patients in critical conditions.

Ngo Thanh Son, deputy general director of VMED Group, said, “We are proud to join HUST to create a high-technology product to promptly deliver to the hotbeds of Covid-19 and quickly help hospitals treat Covid-19 patients.”

“With its contribution, Petrosetco hopes that these products will help frontline doctors promptly save Covid-19 patients so that the country can overcome the Covid-19 pandemic as soon as possible,” said Petrosetco Chairman Phung Tuan Ha.

In the second phase, HUST and VMED Group will begin the mass production of HFNC.